Literature DB >> 34549313

Articular cartilage degeneration and bone adaptation due to lack of dystrophin in mice.

José Fontes Dos Santos1, Mariana Cruz Lazzarin1, Vivianne Izabelle de Araújo Baptista1, Hananiah Tardivo Quintana1, Daniel Araki Ribeiro1, Flavia de Oliveira2.   

Abstract

INTRODUCTION: Duchenne muscular dystrophy is caused by the absence of dystrophin. This study aimed to investigate femoral morphological characteristics of lack of dystrophin in MDX mice, considering that this model, different from DMD patient, is not influenced by corticosteroids administration and limited ambulation.
MATERIALS AND METHODS: Proximal femur of male 16-week-old Control and MDX mice were submitted to histological, morphometric (volume density of articular cartilage, compact bone, trabecular bone and bone marrow; articular cartilage layers area; articular cartilage cell area), and immunohistochemistry analysis for RUNX-2, RANK-L, MMP-2, MMP-9, Caspase-3 and KI-67.
RESULTS: MDX showed loss of linearity of articular cartilage with subchondral bone transition and elevation of this subchondral bone to the articular surface when compared with control. In addition, MDX presented morphological difference in the pantographic network of collagen fibers. Volume density of trabecular bone tissue was higher in the MDX than Control, but volume density of articular cartilage was lower in MDX (p < 0.05). The articular cartilage layers and chondrocytes area were significantly smaller in MDX than Control. These results associated to MMPs and osteogenic markers of proximal femur revealed an adaptation process as a consequence of lack of dystrophin.
CONCLUSIONS: The morphological changes observed in the bone tissue of the MDX may be not only secondary to muscle weakness or chronic use of corticosteroids but also our results indicate connections between decrease of cartilage thickness, collagen network alteration and consequent subchondral changes that may lead to articular cartilage degeneration and bone adaptation mechanism in MDX mice.
© 2021. The Japanese Society Bone and Mineral Research.

Entities:  

Keywords:  Articular cartilage; Bone; Collagen; Duchenne muscular dystrophy; MDX mice

Mesh:

Substances:

Year:  2021        PMID: 34549313     DOI: 10.1007/s00774-021-01270-x

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  37 in total

Review 1.  The muscular dystrophies: from genes to therapies.

Authors:  Richard M Lovering; Neil C Porter; Robert J Bloch
Journal:  Phys Ther       Date:  2005-12

2.  Fracture prevalence in Duchenne muscular dystrophy.

Authors:  Denise G M McDonald; Maria Kinali; Andrew C Gallagher; Eugenio Mercuri; Francesco Muntoni; Helen Roper; Philip Jardine; David Hilton Jones; M G Pike
Journal:  Dev Med Child Neurol       Date:  2002-10       Impact factor: 5.449

3.  Eteplirsen for the treatment of Duchenne muscular dystrophy.

Authors:  Jerry R Mendell; Louise R Rodino-Klapac; Zarife Sahenk; Kandice Roush; Loren Bird; Linda P Lowes; Lindsay Alfano; Ann Maria Gomez; Sarah Lewis; Janaiah Kota; Vinod Malik; Kim Shontz; Christopher M Walker; Kevin M Flanigan; Marco Corridore; John R Kean; Hugh D Allen; Chris Shilling; Kathleen R Melia; Peter Sazani; Jay B Saoud; Edward M Kaye
Journal:  Ann Neurol       Date:  2013-09-10       Impact factor: 10.422

4.  Mechanical, biochemical and morphometric alterations in the femur of mdx mice.

Authors:  Wilson Romero Nakagaki; Celso Aparecido Bertran; Cintia Yuri Matsumura; Humberto Santo-Neto; José Angelo Camilli
Journal:  Bone       Date:  2010-09-17       Impact factor: 4.398

5.  Regional changes in bone area and bone mineral content in boys with duchenne muscular dystrophy receiving corticosteroid therapy.

Authors:  Nicola J Crabtree; Helen Roper; Heather McMurchie; Nicholas J Shaw
Journal:  J Pediatr       Date:  2009-11-02       Impact factor: 4.406

6.  Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy.

Authors:  Cuixia Tian; Brenda L Wong; Lindsey Hornung; Jane C Khoury; Lauren Miller; Jean Bange; Irina Rybalsky; Meilan M Rutter
Journal:  Neuromuscul Disord       Date:  2016-08-22       Impact factor: 4.296

7.  Influences on skeletal mineralization in children and adolescents: evidence for varying effects of sexual maturation and physical activity.

Authors:  C W Slemenda; T K Reister; S L Hui; J Z Miller; J C Christian; C C Johnston
Journal:  J Pediatr       Date:  1994-08       Impact factor: 4.406

8.  Skeletal health in Duchenne dystrophy: bone-size and subcranial dual-energy X-ray absorptiometry analyses.

Authors:  Wendy M King; John T Kissel; Diane Visy; Prem K Goel; Velimir Matkovic
Journal:  Muscle Nerve       Date:  2014-02-26       Impact factor: 3.217

9.  Low bone mineral density and decreased bone turnover in Duchenne muscular dystrophy.

Authors:  Ann-Charlott Söderpalm; Per Magnusson; Anne-Christine Ahlander; Jón Karlsson; Anna-Karin Kroksmark; Már Tulinius; Diana Swolin-Eide
Journal:  Neuromuscul Disord       Date:  2007-07-12       Impact factor: 4.296

10.  Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy.

Authors:  Paul M L Janssen; Jason D Murray; Kevin E Schill; Neha Rastogi; Eric J Schultz; Tam Tran; Subha V Raman; Jill A Rafael-Fortney
Journal:  PLoS One       Date:  2014-02-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.